NPCE PE Ratio & Valuation,Is NPCE Overvalued

NPCE Relative Valuation

NPCE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NPCE is overvalued; if below, it's undervalued.

Historical Valuation

Neuropace Inc (NPCE) is now in the Fair zone, suggesting that its current forward PS ratio of 5.61 is considered Fairly compared with the five-year average of -8.86. The fair price of Neuropace Inc (NPCE) is between 9.18 to 21.33 according to relative valuation methord.

Relative Value

Fair Zone

9.18-21.33

Current Price：16.08

Fair

-23.77

-42.09

EV/EBITDA

Neuropace Inc. (NPCE) has a current EV/EBITDA of -42.09. The 5-year average EV/EBITDA is -13.91. The thresholds are as follows: Strongly Undervalued below -36.94, Undervalued between -36.94 and -25.43, Fairly Valued between -2.40 and -25.43, Overvalued between -2.40 and 9.12, and Strongly Overvalued above 9.12. The current Forward EV/EBITDA of -42.09 falls within the Strongly Undervalued range.

-27.43

EV/EBIT

Neuropace Inc. (NPCE) has a current EV/EBIT of -27.43. The 5-year average EV/EBIT is -10.92. The thresholds are as follows: Strongly Undervalued below -28.89, Undervalued between -28.89 and -19.91, Fairly Valued between -1.94 and -19.91, Overvalued between -1.94 and 7.05, and Strongly Overvalued above 7.05. The current Forward EV/EBIT of -27.43 falls within the Undervalued range.

5.61

Neuropace Inc. (NPCE) has a current PS of 5.61. The 5-year average PS is 4.11. The thresholds are as follows: Strongly Undervalued below -1.18, Undervalued between -1.18 and 1.47, Fairly Valued between 6.76 and 1.47, Overvalued between 6.76 and 9.41, and Strongly Overvalued above 9.41. The current Forward PS of 5.61 falls within the Historic Trend Line -Fairly Valued range.

-61.63

P/OCF

Neuropace Inc. (NPCE) has a current P/OCF of -61.63. The 5-year average P/OCF is -13.39. The thresholds are as follows: Strongly Undervalued below -34.98, Undervalued between -34.98 and -24.18, Fairly Valued between -2.59 and -24.18, Overvalued between -2.59 and 8.20, and Strongly Overvalued above 8.20. The current Forward P/OCF of -61.63 falls within the Strongly Undervalued range.

-41.14

P/FCF

Neuropace Inc. (NPCE) has a current P/FCF of -41.14. The 5-year average P/FCF is -12.51. The thresholds are as follows: Strongly Undervalued below -30.47, Undervalued between -30.47 and -21.49, Fairly Valued between -3.53 and -21.49, Overvalued between -3.53 and 5.45, and Strongly Overvalued above 5.45. The current Forward P/FCF of -41.14 falls within the Strongly Undervalued range.

Neuropace Inc (NPCE) has a current Price-to-Book (P/B) ratio of 29.11. Compared to its 3-year average P/B ratio of 17.88 , the current P/B ratio is approximately 62.80% higher. Relative to its 5-year average P/B ratio of 12.41, the current P/B ratio is about 134.52% higher. Neuropace Inc (NPCE) has a Forward Free Cash Flow (FCF) yield of approximately -3.08%. Compared to its 3-year average FCF yield of -14.32%, the current FCF yield is approximately -78.52% lower. Relative to its 5-year average FCF yield of -16.67% , the current FCF yield is about -81.55% lower.

29.11

P/B

Median3y

17.88

Median5y

12.41

-3.08

FCF Yield

Median3y

-14.32

Median5y

-16.67

Competitors Valuation Multiple

The average P/S ratio for NPCE's competitors is 8.81, providing a benchmark for relative valuation. Neuropace Inc Corp (NPCE) exhibits a P/S ratio of 5.61, which is -36.34% above the industry average. Given its robust revenue growth of 29.89%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of NPCE increased by 44.68% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -13.00 to -21.51.

The secondary factor is the Revenue Growth, contributed 29.89%to the performance.

Overall, the performance of NPCE in the past 1 year is driven by P/E Change. Which is more unsustainable.

29.89%

21.06M → 27.35M

Revenue Growth

-50.64%

-25.89 → -12.78

Margin Expansion

65.43%

-13.00 → -21.51

P/E Change

44.68%

11.19 → 16.19

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Neuropace Inc (NPCE) currently overvalued or undervalued?

What is Neuropace Inc (NPCE) fair value?

NPCE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Neuropace Inc (NPCE) is between 9.18 to 21.33 according to relative valuation methord.

How does NPCE's valuation metrics compare to the industry average?

What is the current P/B ratio for Neuropace Inc (NPCE) as of Dec 15 2025?

As of Dec 15 2025, Neuropace Inc (NPCE) has a P/B ratio of 29.11. This indicates that the market values NPCE at 29.11 times its book value.

What is the current FCF Yield for Neuropace Inc (NPCE) as of Dec 15 2025?

As of Dec 15 2025, Neuropace Inc (NPCE) has a FCF Yield of -3.08%. This means that for every dollar of Neuropace Inc’s market capitalization, the company generates -3.08 cents in free cash flow.

What is the current Forward P/E ratio for Neuropace Inc (NPCE) as of Dec 15 2025?

As of Dec 15 2025, Neuropace Inc (NPCE) has a Forward P/E ratio of -23.77. This means the market is willing to pay $-23.77 for every dollar of Neuropace Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Neuropace Inc (NPCE) as of Dec 15 2025?

As of Dec 15 2025, Neuropace Inc (NPCE) has a Forward P/S ratio of 5.61. This means the market is valuing NPCE at $5.61 for every dollar of expected revenue over the next 12 months.

NPCE Valuation